Snakebite Season Sees Hope for a Breakthrough Antivenom
It is currently the “snake season,” when snakebite incidents frequently occur.
The top academic journal Cell recently published online a study entitled “A Cocktail Therapy of Varespladib Combined with Broad-Spectrum Neutralizing Human Antibodies Protects Against Snake Venom”. The article reported that, by using the blood samples of one man, scientists successfully developed a “broad-spectrum antivenom serum.”
According to the study, over the past 18 years, reptile enthusiast Tim Friede subjected himself to a remarkable experiment: in order to raise venomous snakes without being killed, he deliberately exposed himself to venom—either by allowing snakes to bite him or by directly injecting venom into his body—856 times in total.
These included encounters with deadly snakes such as mambas, rattlesnakes, and cobras. Yet Friede not only survived but also provided the global medical community with invaluable material for developing potential therapies.
In mouse experiments, serum derived from his blood was shown to neutralize lethal doses of venom from 13 snake species. Experts stated, “Once such a serum enters clinical practice, its long-term impact could be revolutionary, fundamentally changing the treatment of snakebite envenomation.”
From Hobby to Self-Experimentation
After more than a decade of repeated exposure, broad-spectrum antibodies capable of neutralizing multiple snake venoms were detected in Friede’s blood.
He called this process of self-immunization “venom training.”
Friede’s story first went viral in 2016, when internet users nicknamed him the “real-life Venom.” At the time, immunologist Jacob Glanville came across the news and reached out. “We exchanged a few pleasantries, and then I asked him for a few tubes of blood for research,” Glanville recalled.
Glanville, who had long been committed to developing universal vaccines, began studying snake venoms around 2015. He hypothesized that although different venoms contain unique lethal proteins and enzymes, there may be structural similarities across species—making it possible to develop broad-spectrum neutralizing antibodies.
This idea inspired him to found the biotech company Centivax and to recruit structural vaccinologist Peter Kwong of Columbia University. Together, they launched a program based on human serum research.
Traditionally, antivenoms are made by injecting venom into animals such as horses or sheep, harvesting their blood, and extracting antibodies. But since these are animal-derived proteins, they often trigger allergic reactions in patients and can only be administered in hospitals equipped for emergency care.
In addition, with over 600 venomous snake species worldwide, each with geographically distinct toxins, developing effective antivenoms has been difficult. In 2018, a PLOS journal reported that several approved antivenoms were ineffective against many Indian snakes.
This explains why clinical outcomes for snakebites have been poor, with many victims dying en route to hospitals.
In June 2017, the World Health Organization (WHO) classified snakebite envenoming as a “high-priority neglected tropical disease,” noting that up to 137,880 people die annually and about 400,000 suffer amputations or permanent disability.
Against this backdrop, Friede readily agreed when Glanville asked for blood donations—since finding a better antivenom had always been part of his mission.
The Making of a “Human Antivenom”
Friede’s passion began in high school, when he started keeping reptiles. Initially, he collected harmless or mildly venomous snakes from fields. Later, he added highly venomous species to his collection, constantly facing the risk of a fatal bite.
He realized that if he wanted to continue, he had to “train” his immune system. He began milking venom from snakes, diluting it, and injecting it into himself—or simply allowing the snakes to bite him. “There was no manual, so I had to figure it out on my own—taking photos, keeping notes, and optimizing the process,” he told National Geographic (UK).
In 2001, disaster struck: Friede was bitten twice by a cobra within one hour. He was hospitalized, spent four days in a coma, and upon awakening, immediately wrote a detailed bite report. “The pain was excruciating—about 100 times worse than a bee sting.”
By 2018, Friede had endured over 200 deliberate snakebites and nearly 700 venom injections, using venoms from 16 infamous species, including the neurotoxic taipan, the deadly Egyptian cobra, and the aggressive Mojave rattlesnake.
“We believe Friede’s body has generated antibodies capable of counteracting multiple neurotoxic venoms,” Glanville explained. With ethical approval and Friede’s consent, the team extracted 40 ml of his blood.
A Breakthrough “Cocktail Therapy” Against 19 Snake Venoms
The results, published in Cell, were striking.
By analyzing memory B cells from Friede’s blood, the team identified two broadly neutralizing antibodies:
LNX-D09 (targets long-chain neurotoxins)
SNX-B03 (targets short-chain neurotoxins)
These toxins are the main lethal components in cobra-family venoms. By binding to nerve cell receptors, they block communication between neurons, leading to paralysis and respiratory failure.
In mouse experiments, these antibodies neutralized venoms from several dangerous species including the black mamba and king cobra—both listed by WHO as high-risk snakes.
The researchers then formulated a “cocktail therapy,” combining the two antibodies with varespladib, an investigational broad-spectrum oral antidote.
Although a 2024 Phase II trial of varespladib alone did not meet its primary endpoint, patients who received it within five hours of a snakebite showed positive signs: lower disease severity, faster recovery, and improved function.
In preclinical testing, the cocktail fully neutralized the venoms of 13 cobra-family snakes—including the black mamba and taipan—and significantly extended survival in mice challenged with six additional venoms.
“Our next step is to analyze Friede’s blood for components effective against viper-family venoms,” Kwong said. Unlike cobras, vipers mainly produce hematotoxins.
The ultimate goal: to develop either a universal broad-spectrum antivenom or at least two broad-spectrum formulations—one for cobras and one for vipers.
Steven Hall, a snake venom pharmacologist at Lancaster University, called the research “unprecedented, highly clever, and creative.” He noted that human-derived antibodies are safer, with lower risk of fatal allergic reactions, and praised the cocktail approach: “If it reaches clinical use, the long-term impact could be revolutionary.”
Field trials are planned in Australia, where cobra-family snakes predominate. Veterinarians will test the cocktail in dogs bitten by snakes. If ineffective within minutes, standard antivenoms will be administered.
Ethical and Practical Concerns
Some researchers, however, voiced unease. Evolutionary biologist Kartik Sunagar of the Indian Academy of Sciences warned that the therapy’s origins in dangerous self-experimentation were troubling: “I worry this might inspire others to imitate Friede’s behavior.”
Glanville stressed repeatedly, “We strongly discourage anyone from repeating Friede’s actions—there is no need, since we have already identified the antibodies.”
Still, Sunagar noted that Friede’s exposures were mostly to North American venoms, raising doubts about efficacy against Australian species like the inland taipan, the world’s most venomous land snake.
Even if effective, he added, costs may prevent widespread adoption: “As a cocktail of small molecules and monoclonal antibodies, I am not sure it can be made affordable to the general public.”
Glanville acknowledged the challenge: “Most snakebite victims are poor, living in developing countries. Profit margins are very low. We envision a simple, stable formulation—perhaps a syringe that can be stored at room temperature and used even in rural clinics.”
Jean-Philippe Chippaux, an honorary fellow at France’s Institute of Sustainable Development, emphasized that the greatest challenge in snakebite treatment remains timeliness. Past clinical practice has shown that, even without species-specific antivenoms, early and sufficient use of available antivenoms can save lives.
For example, in 2020, doctors in Huizhou, China, successfully treated a patient bitten by a Russell’s viper by using large doses of other available antivenoms.
A Life Devoted to Venom Research
Today, Friede has left his job as a truck mechanic and works as head of Centivax’s reptile division. His home still houses dozens of venomous snakes.
His wife once begged him to stop self-experimenting, fearing not only for his health but also for their son’s safety. When he refused, she left with the child.
Friede admitted: “I haven’t been a good husband or father. But for me, finding a broad-spectrum antivenom is more important than my family.”